Browse
Submit Data
Databases
API
Help

Dataset Information

3 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Monitoring advanced adenoma and early colorectal cancer by urine metabolomics

ABSTRACT: Interventions: Control Group:none;Advanced Adenoma Group:none;Early Colorectal Cancer Group:none Primary outcome(s): urine metabolomics Study Design: Factorial

DISEASE(S): Advanced Adenoma, Colorectal Cancer

PROVIDER: 2702218 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Urine Metabolomics and Colorectal Cancer Screening

Project description:This is a prospective, multi-centered study to assess whether urine metabolomics can play a role in the screening of colorectal cancer (CRC). Urine samples will be collected from 1000 patients going through an established CRC screening program, and from a further 500 patients who already have a diagnosis of CRC. Using nuclear magnetic resonance (NMR) spectroscopy, the 1H NMR spectrum of urine samples will be analyzed for specific metabolites, and establish the metabolomic signature of colorectal cancer. The results from metabolomic urinalysis of this screening cohort will be compared with results from colonoscopy, histological descriptions, fecal occult blood testing (FOBT), and fecal immune testing (FIT) to assess the accuracy of urine metabolomics in identifying patients with polyps and malignancies. The urine metabolomic results from the colorectal cancer group will be correlated with operative, histological and clinical staging to define the role of urine metabolomics in assessing colorectal cancer type, location and stage. Additionally approximately 300 urine samples from breast cancer patients and 300 from prostate cancer patients will be collected to validate that the colorectal cancer signature is unique.

| 2116822 | ecrin-mdr-crc

Effect of intestinal microbiome diversity on the efficacy and survival of chemotherapy for advanced non-small cell lung cancer

Project description:Interventions: Response Group:none;None Response Group:Nil Primary outcome(s): CR;PR;SD;PD;PFS;OS;Gut microbiome;Fecal metabolomics;Immune factor Study Design: Factorial

| 2689133 | ecrin-mdr-crc

LC-MS-based urine metabolomics analyses for early diagnosis of medulloblastoma

Project description:we applied liquid chromatography - mass spectrometry (LC-MS) based metabolomics to analyze a cohort including 420 urine samples

2019-11-27 | PXD016453 | iProX

Mining the Human Urine Proteome for Monitoring Renal Transplant Injury

Project description:Gene expression data was analyzed to map with urine proteomics data gene expression data from kidney biopsies from kidney transplant patients with and without acute rejection, chronic allograft nephropathy and BK virus nephritis was used to study gene expression changes during acute rejection, chronic allograft nephropathy and bk virus nephropathy. Samples labeled STA16, STA22, STA14, and STA18 were included in the CAN vs no-CAN analysis as no-CAN samples as they also qualified as non-CAN samples.

2017-08-22 | GSE75693 | GEO

Real-time health monitoring through urine metabolomics.

Project description: Not available

| S-EPMC6848197 | biostudies-literature

Urine

Project description:Urine Raw sequence reads

| PRJNA850668 | ENA

Exploring the effect of different surgical methods on the prognosis of patients with colorectal cancer based on multiple omics

Project description:Interventions: left hemicolectomy:None;right hemicolectomy:None;sigmoid resection:None;radical rectal cancer:None;low rectal resection with prophylactic ileostomy:None Primary outcome(s): Fecal high-throughput sequencing;Fecal Metabolomics;immunomics Study Design: Factorial

| 85716 | ecrin-mdr-crc

Podocyte-released migrasomes in urine serve as an indicator for early podocyte injury

Project description:miRNA microarray was performed for migrasomes and exosomes derived from urine

2020-05-14 | GSE150459 | GEO

Urine Proteomics for Noninvasive Monitoring of Biomarkers in Bronchopulmonary Dysplasia

Project description:Current techniques to diagnose and/or monitor critically ill neonates with bronchopulmonary dysplasia (BPD) require invasive sampling of body fluids, which can affect the health status of these frail neonate. We tested our hypotheses 1) it is feasible to use early urine samples from extremely low gestational age newborns at risk for bronchopulmonary dysplasia for proteomics, and 2) urine proteomics can confirm previously identified proteins and biomarkers associated with BPD without invasive sample collection. We developed a robust high throughput urine proteomics methodology that requires only 50 microliters of urine. We validated the methodology on urine collected within 72 hours of birth. Urine samples were collected from extremely low gestational age newborns (ELGANS) (gestational age (26 + 1.2) weeks) admitted to a single Neonatal Intensive Care Unit(NICU); half of whom eventually developed BPD, while the other half served as controls. Our high throughput urine proteomics approach clearly identified several BPD-associated changes in the urine proteome recapitulating expected blood proteome changes. Interestingly, sixteen identified urinary proteins are known targets of drugs approved by the Food and Drug Administration (FDA). Urine proteomics can be used for prediction of BPD risk. In addition to identifying numerous proteins implicated in BPD pathophysiology, previously found in invasively collected blood, tracheal aspirate, and broncho-alveolar lavage, urine proteomics also suggested novel potential therapeutic targets. Ease of access to urine for sequential proteomic evaluations could also allow for longitudinal monitoring of disease progression and impact of therapeutic intervention.

2022-04-04 | PXD028895 | Pride

urine metagenome

Project description:source-separated urine Metagenome

| PRJNA399057 | ENA